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Dangerous debris
 
According to a study on page 1575,
cellular debris might help trigger the
autoimmune disease systemic lupus
erythematosus (SLE). Vollmer and col-
leagues show that endogenous complexes
of RNA and protein, often released from
dying cells, engage activating receptors in
dendritic cells (DCs). The activated DCs
then launch an inappropriate immune re-
sponse against these self-complexes, thus
triggering autoimmune disease.
In patients with SLE, the clearance
of apoptotic cells is often delayed, in
part because of unexplained defects in
macrophage phagocytosis. As a result,
cellular debris accumulates and is
thought to be a source of autoantigens.
But a simple piling up of undisposed
waste does not explain the specificity
of the autoantibody response in pa-
tients with SLE—a response selectively
targeted against nucleic acid–contain-
 
NPY’s mixed messages
 
A stress hormone sends mixed signals to immune cells, according to a study on page 1527. 
Wheway and colleagues show that neuropeptide Y (NPY) activates antigen-presenting cells 
(APCs) but shuts off T cells. If correctly sequenced, these activities would both turn on and 
then limit certain immune responses.
NPY is an abundant neuropeptide that is released from sympathetic nerve endings. In the 
brain, NPY regulates physiological and emotional processes, including metabolism, heart rate, 
and depression. NPY is also produced by activated immune cells and has been shown to dampen 
cytokine production by macrophages and inhibit the killer activity of natural killer cells.
The effects of NPY on T cells, however, have been controversial. Treatment with NPY 
ameliorates autoimmune disease in a mouse model of multiple sclerosis, suggesting a 
suppressive effect on the disease-inducing T helper (Th)-1 cells. But mice lacking the major 
lymphoid receptor for NPY (Y1) were protected from colitis, another Th1-driven 
autoimmune disease, suggesting that NPY signaling normally activates Th1 cells.
The study by Wheway and colleagues helps clear up these conflicting reports. They 
show that NPY indeed inhibits Th1 responses, as T cells from Y1-deficient mice produced 
more interferon (IFN)-
 
 
 
 than wild-type cells when stimulated in vitro. When transferred, 
Y1-deficient T cells were hyperactive and triggered more severe colitis in recipient mice 
than did wild-type T cells.
However, the receptor-deficient mice themselves were resistant to T cell–mediated 
colitis when treated with an intestinal irritant. The defect was traced to APCs, which could 
not be activated in the absence of NPY signaling. APCs from the Y1-deficient mice failed to 
produce the Th1-promoting cytokines interleukin-12 and TNF and could not activate naive 
T cells. These mice were thus protected because the T cell response never got started.
Neuropeptide Y (NPY) stimulates cytokine 
production from antigen-presenting cells, 
but inhibits it from T cells.
 
How is a T cell response ever mounted if the same signal that turns on the APC turns off the T cell? The authors 
suspect that it comes down to timing. The expression of the Y1 receptor on T cells might be induced only after 
activation, thus providing a negative feedback loop that keeps activated T cells from running amok. The authors 
now plan to study NPY-induced signaling in different cell types to determine how the same molecule tells some 
cells to go and others to stop. 
 
ing molecules, including chromatin
and small nuclear ribonucleoproteins
(snRNPs).
Vollmer and colleagues now show
that snRNPs, such as U1, can be taken
up by human DCs when complexed
with antibodies from SLE serum. Once
inside, the RNA component of the
snRNPs engages the intracellular recep-
tors Toll-like receptor (TLR)-7 and
TLR8—which are normally triggered
U1 snRNPs bind to TLR7 and drive cytokine 
production by human dendritic cells.
 
by microbial RNAs—thus activating
the immune response. The ability to
engage TLR7 depended on uridine-rich
sequences in the U1 RNA. These
sequences were also found in other
autoantigens targeted in SLE, suggesting
that the ability to engage intracellular
TLRs might be a key to autoantibody
specificity in SLE.
How the process of autoantibody
formation is initiated is still unclear.
Recent studies have shown evidence for
tolerance defects in patients with SLE
that allow autoreactive antibody-pro-
ducing B cells to escape deletion. Others
have shown that RNA-associated auto-
antigens can trigger TLR7 signaling in
B cells, suggesting the possibility that
autoreactive B cell escapees and immune-
stimulating DCs conspire to trigger an
immune response against RNA-associ-
ated antigens. 
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